https://www.nasdaq.com/press-release/aridis-pharmaceuticals-ceo-discusses-monoclonal-antibody-cocktail-protection-against
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-a-pan-coronavirus-monoclonal-antibody-cocktail-that
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-third-quarter-2021-results-2021-11-10
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-second-quarter-2021-results-2021-08-12
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-%2425-million-registered-direct-offering-priced-at-a
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-covid-mab-ranks-among-the-top-5-most-potent-covid-19-mabs
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-exclusive-license-of-suvratoxumab-a-phase-3-ready
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-covid-mab-ar-712-neutralizes-sars-cov-2-delta-variant-2021-07
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-first-quarter-2021-results-2021-05-13
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-2020-fourth-quarter-and-year-end-financial-results
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-interview-to-air-on-bloomberg-television-u.s.-on-the-redchip
https://www.nasdaq.com/press-release/aridis-enters-into-apextm-licensing-and-product-discovery-agreement-for-zoonotic
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-provides-multiple-program-updates-including-the-addition-of-a
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-host-fireside-chat-with-analysts-to-discuss-2021-outlook
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-third-quarter-2020-results-2020-11-20
https://www.nasdaq.com/press-release/c-o-r-r-e-c-t-i-o-n-aridis-pharmaceuticals-inc.-2020-10-27
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-reports-positive-preclinical-efficacy-data-of-a-highly
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-%248.5-million-registered-direct-offering-2020-10-14
https://www.nasdaq.com/press-release/aridis-announces-agreement-with-the-fda-on-updated-phase-2-clinical-trial-design-for
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2020-09-04
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-second-quarter-2020-results-2020-08-11
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-participate-in-cantor-fitzgerald-virtual-symposium%3a-winning
https://www.nasdaq.com/press-release/aridis-reports-ar-501-clinical-data%3a-positive-safety-data-in-healthy-subjects-of-a
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-discuss-apextm-in-virtual-fireside-chat-hosted-by-cantor
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-appoints-dr.-hasan-jafri-as-chief-medical-officer-2020-06-15
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-first-quarter-2020-results-2020-05-12
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-enrolls-its-first-covid-19-patient-in-ongoing-phase-3-ar-301
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-participate-in-maxim-groups-infectious-disease-virtual
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-2019-fourth-quarter-and-year-end-financial-results
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-postpone-investor-day-due-to-coronavirus-concerns-2020-03
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-present-at-the-32nd-annual-roth-conference-2020-03-05
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-provides-update-on-investor-day-featuring-key-opinion-leader
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-host-investor-day-showcasing-apextm-technology-platform-and
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-presents-apextm-antibody-discovery-and-production-platform
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-third-quarter-2019-results-2019-11-13
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-appoints-infectious-disease-expert-paul-mendelman-md-as
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-executes-license-agreement-with-the-serum-institute-of-india
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-present-ar-105-and-ar-501-gallium-citrate-data-at-idweektm
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-to-present-at-the-h.c.-wainwright-21st-annual-global
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-reports-phase-2-clinical-trial-results-of-ar-105-for-the
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-second-quarter-2019-results-2019-08-12
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-enters-into-equity-purchase-and-option-agreements-with-the
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-receives-orphan-drug-designation-from-the-european-medicines
